Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Melinta Therapeutics, LLC Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris May 23, 2024 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID December 05, 2023 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023 October 11, 2023 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection) July 31, 2023 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens July 10, 2023 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada May 15, 2023 From Melinta Therapeutics, LLC Via Business Wire Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis March 22, 2023 From Melinta Therapeutics, LLC Via Business Wire Tickers CDTX Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis January 25, 2023 From Melinta Therapeutics, LLC Via Business Wire Tickers CDTX Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event November 30, 2022 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022 October 18, 2022 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S. July 27, 2022 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics April 06, 2022 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs March 14, 2022 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio January 06, 2022 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development October 25, 2021 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy July 06, 2021 From Melinta Therapeutics, LLC Via Business Wire Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer June 29, 2021 From Melinta Therapeutics, LLC Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.